Status:
UNKNOWN
Travoprost Ophthalmic Topical Cream for Open-angle Glaucoma or Ocular Hypertension
Lead Sponsor:
Glaukos Corporation
Conditions:
Open Angle Glaucoma
Ocular Hypertension
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The goal of this clinical trial is to learn about the safety of Travoprost Ophthalmic Topical Cream and how well it works in lowering high intraocular pressure (IOP) in patients with open-angle glauco...
Eligibility Criteria
Inclusion
- Male or female, 18 years of age or older at the Screening Visit;
- Willing and able to provide written informed consent on the IRB/IEC-approved informed consent form;
- Diagnosis of OAG (including pigmentary and pseudoexfoliative) or OHT in both eyes;
- Qualifying IOP in the study eye;
- Best-corrected visual acuity of approximately 20/80 Snellen in each eye
Exclusion
- Sensitivity or allergy to travoprost or timolol;
- Bronchial asthma, a history of bronchial asthma, or severe chronic obstructive pulmonary disease;
- History of or current sinus bradycardia, second- or third-degree atrioventricular block, overt cardiac failure, or cardiogenic shock;
- History of cerebrovascular insufficiency;
- Any form of glaucoma other than open-angle glaucoma
- Advanced visual field loss or cup-to-disc ratio of 0.8 or greater
- Non-qualifying prior surgeries or procedures in either eye
Key Trial Info
Start Date :
November 15 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 1 2024
Estimated Enrollment :
250 Patients enrolled
Trial Details
Trial ID
NCT06152861
Start Date
November 15 2023
End Date
August 1 2024
Last Update
December 6 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Glaukos Clinical Study Site
Newport Beach, California, United States, 92663